Skip to main content

Procter & Gamble to Use Eagle Genomics' Bioinformatics Platform for R&D

NEW YORK (GenomeWeb) – Eagle Genomics said today that Procter & Gamble has signed a four-year agreement with the company to deploy Eaglecore, its bioinformatics software platform, for use in its internal research and development activities.

Specially, P&G's global biotechnology and life science division will use Eaglecore in its efforts to develop new products, organize data, and integrate legacy and more recent data for analysis purposes. The cloud-based software, which launched last September, provides tools for capturing, annotating, and sharing data among other capabilities. As part of the deal, Eagle will provide additional data curation services.

This deal builds on an existing partnership involving Eagle's consultancy arm, which P&G has tapped to support past research efforts.

Financial and other terms of the licensing agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.